Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of frexalimab in multiple sclerosis
2026-525688-41-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 41
01
Overview
Phase 3, open-label, single-arm trial of frexalimab in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Sanofi. Primary endpoint: Long-term safety and tolerability. Planned start Oct 2026; status: authorised.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2026-525688-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525688-41-00.